Israeli research shows that the coronavirus vaccine produced by Pfizer is not only It not only protects people who are vaccinated against COVID-19, but also prevents people with immunity from spreading the disease to others.
The question of whether vaccines will prevent vaccine people from becoming carriers is a critical issue as vaccination is spread worldwide.
Clinical research conducted by Israel’s largest health fund Clalit showed a significant decrease in infections in 200,000 people aged 60 and over two weeks after receiving their first vaccination. Not everyone in the 200,000 people involved in the research was vaccinated.
Ran Balicer, Clalit’s head of innovation, said there was no impact on infection rates generally five to 12 days after receiving the first two-stage vaccinations.
According to the data, there was a slight decrease in the illness on Day 13, but by Day 14 the spread of the disease was 33% lower between vaccinated and unvaccinated people.
Israel began vaccinating its population using Pfizer vaccine on December 20, 2020.So far, the country has given the first two vaccinations to nearly 2 million people and has started a second.
This is the first evidence that the Pfizer vaccine is not only But it only prevents people from contracting COVID-19 after being exposed to the coronavirus. But also prevents the exposed person from transmitting the virus to others.
It is not clear if the first vaccine reduced the illness by more than 33% or what percentage of the second dose after the second dose. But Israeli health experts believe the data shows a significant decrease in the spread of the virus.
Prof Baliser said that although the results were preliminary, they were “very encouraging”.
“It is important to remember that these results do not show that there is full protection against this disease,” he said.
“Therefore, people who receive the vaccine must still be careful, wear masks and follow public health regulations” to protect those around them.
Balicer said experts hope to prove in the coming weeks that the vaccine will also reduce serious COVID cases and hospitalization for people living with the infection.